about
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?Expert perspectives on biosimilar monoclonal antibodies in breast cancerCost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell CarcinomaClinical considerations for biosimilar antibodies.Rituximab and biosimilars - equivalence and reciprocity.The economic burden of fragile x syndrome: healthcare resource utilization in the United States.The approval process for biosimilar erythropoiesis-stimulating agentsThe cost-effectiveness of biopharmaceuticals: a look at the evidence.Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Biosimilars of low-molecular-weight heparin products: fostering competition or reducing 'biodiversity'?Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry.Cost-effectiveness of enzyme replacement therapy for Fabry diseaseEconomic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.Biosimilars: part 2: potential concerns and challenges for p&t committees.Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysisSimilar biotherapeutic products: overview and reflections.Biosimilarity Versus Manufacturing Change: Two Distinct Concepts.Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.Projecting expenditure on medicines in the UK NHS.Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.Biosimilars: part 1: proposed regulatory criteria for FDA approval.Follow-on biologics in oncology - the need for global and local regulations.How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.Improving Access to Cancer Treatments: The Role of Biosimilars.The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.Tocilizumab (Actemra).Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.Analytical characterization of recombinant hCG and comparative studies with reference product.Reimbursement of biosimilars in Poland: is there a link to health technology assessment?The role of biosimilars in value-based oncology care
P2860
Q26863707-FE0CC96D-1983-4759-ACA8-8F54566FA2E8Q26865410-B45D5576-4A14-4B7A-9CC5-30D3D91EF544Q28551507-9BEB3100-4DD3-44B0-A530-3E9C0901178AQ30377239-60BDEDD6-96A1-4455-BBDB-BCDF0CC7A68CQ33596879-37CA90CF-3AF2-4536-A8DD-62B6772E9EDFQ33652798-CF70A65C-E6C1-45EA-9836-6F4A59B287C2Q34124734-4E94EEBE-9A72-4261-A937-79C46F1B9DBCQ34257719-32C49C45-1371-42A0-8124-102C540131ADQ34352446-49C7DAF3-A5ED-47BB-8DB6-58515B7FED5CQ35162053-B3AA972D-5DA1-4A31-9CB8-1FE7D23543A2Q35880101-440354A5-B626-416D-868D-389F35D46CCDQ36164727-1ED379D2-DE2F-4CB9-A2B0-334FDB7AA247Q36564693-28CACEDD-61E8-4CD3-B851-5AE17ADF5635Q36688268-790E42C2-ACDF-4130-9B99-420BFEBBA0B6Q36768997-F17A0566-8FB8-4FC2-BB99-4AF8A29FF648Q37081551-588FBF27-B1B1-43FC-B33D-89D54D523554Q37599251-7AF8F99D-F180-4D31-A31D-77114EDB9594Q38067449-95A2AE4A-8E70-4365-B0C0-0D10563BDEC7Q38588544-330FFCC2-0C09-4A2D-8E4B-66C6D25DE9BFQ38893192-68E48403-6EF4-4E70-9F7C-BE1D8AA16F2BQ38949634-AFE4C1D1-B1EF-45AB-877E-75699BFEB0E2Q39350064-43236A77-07B9-4399-90AD-D8E19E034BC7Q39403982-3BD31D7E-0CF2-449D-87CB-A783CAA99190Q41535274-B3FD3909-A937-44A5-9241-EE81003EBF07Q42545996-AE7F8908-6E9A-4072-A830-DE15A98F8B58Q43121123-D24DC5FB-A9F7-4DCB-B609-4C2D61B4DC6DQ45074626-BC2FBFD2-FAF6-4D77-9424-5234018E820AQ47099597-38228D2C-E7BB-4ECD-9B9A-FF963C695614Q47760510-D102A9AE-3D5A-478C-9F6E-1411209CABD4Q47978774-D090389F-4294-4EA6-8583-FD9297785B27Q48092457-21B4BE5A-5C10-41A6-8761-95A08852AA3DQ49413206-E208CCEE-0455-4F24-8A26-A19DF68D8246Q53317811-6B6D7ABF-1914-4709-9DAF-7CF9DFF04492Q58605622-6B115828-7573-4735-9B65-615FB1329DE7
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Biosimilar medicines and cost-effectiveness.
@ast
Biosimilar medicines and cost-effectiveness.
@en
type
label
Biosimilar medicines and cost-effectiveness.
@ast
Biosimilar medicines and cost-effectiveness.
@en
prefLabel
Biosimilar medicines and cost-effectiveness.
@ast
Biosimilar medicines and cost-effectiveness.
@en
P2860
P356
P1476
Biosimilar medicines and cost-effectiveness.
@en
P2093
Steven Simoens
P2860
P356
10.2147/CEOR.S12494
P407
P577
2011-02-10T00:00:00Z